• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study reveals structure of a ‘master switch’ controlling cell division

Bioengineer by Bioengineer
May 28, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Understanding the structure of the FoxM1 protein and how it works could guide development of new cancer-fighting drugs

Unregulated cell division is a hallmark of cancer, and one of the key proteins involved in controlling cell division is called FoxM1. Abnormal activation of FoxM1 is a common feature of cancer cells and is correlated with poor prognosis, metastasis, and resistance to chemotherapy.

Now researchers at UC Santa Cruz have determined the structure of this protein–a kind of “master switch” for cell division–in its inactive or “off” conformation. This new understanding of the structure of FoxM1 could ultimately be used to design new drugs that stabilize the protein in its inactive state and thereby stop the uncontrolled proliferation of cancer cells.

Seth Rubin, professor of chemistry and biochemistry at UC Santa Cruz, explained that FoxM1 is a “transcription factor,” a protein that controls the activity of specific genes.

“When a cell is going to divide, there are a bunch of proteins that need to be made, and FoxM1 controls all the genes for those proteins,” Rubin said. “Because cancer cells are proliferating and dividing all the time, they need to activate FoxM1, so it has long been a target for drug development.”

The new study involved a close collaboration between Rubin’s lab and that of Nikolaos Sgourakis, assistant professor of chemistry and biochemistry. After determining the structure of the protein in the “off” state, the team then figured out how it switches from the inhibited conformation to the activated or “on” state. The researchers published their findings May 28 in the journal eLife.

The study revealed that two separate domains of the FoxM1 protein interact and bind together in the inhibited conformation. The study also showed that the two domains separate and lose their structure when the protein is activated. Most proteins fold into an orderly three-dimensional structure that is key to their function, but some proteins function as disordered linear molecules with no particular 3D structure.

“One thing a disordered state is good at is interacting with other proteins,” Rubin said. “With FoxM1, the inactive state is all folded up on itself. When it gets activated it becomes disordered, and then it can recruit the other proteins needed to turn on gene expression. That’s something that hasn’t been seen before, and it may be a general mechanism for how transcription factors switch from the off state to the active state.”

It was known from previous studies that FoxM1 is activated by kinase enzymes, which add phosphoryl groups to specific sites on the protein. Rubin’s team found that phosphorylation of FoxM1 at one particular site causes the dissociation of the two domains and that both domains then become structurally disordered.

“Knowing the structure of the inhibited state of the protein really opens up a pathway to search for compounds that can stabilize it,” Rubin said. “And beyond drug development, in terms of the understanding of how transcription factors work, the discovery of this transition from an ordered to a disordered state is an important advance.”

The determination of the structure was not easy, he said. The researchers used a technique called NMR spectroscopy, taking advantage of a powerful new instrument at the UC Santa Cruz NMR Facility. Rubin’s initial work on FoxM1 was funded by a grant from the Santa Cruz Cancer Benefit Group. The new study was supported by grants from the National Institutes of Health, the American Cancer Society, and Alex’s Lemonade Stand Foundation.

###

In addition to Rubin and Sgourakis, the authors of the paper include co-first authors Aimee Marceau, Caileen Brison, and Santrupti Nerli at UC Santa Cruz, Heather Arsenault and Jennifer Benanti at University of Massachusetts Medical School, and Andrew McShan, Eefei Chen, and Hsiau-Wei Lee at UC Santa Cruz.

Media Contact
Tim Stephens
[email protected]
http://dx.doi.org/10.7554/eLife.46131

Tags: BiologycancerCell BiologyMedicine/HealthMolecular Biology
Share12Tweet7Share2ShareShareShare1

Related Posts

Wearable Devices Improve Parkinson’s Medication Adjustments: Trial

Wearable Devices Improve Parkinson’s Medication Adjustments: Trial

August 21, 2025
How Cancer Affects the Accuracy of Forensic DNA Methylation Age Estimation

How Cancer Affects the Accuracy of Forensic DNA Methylation Age Estimation

August 21, 2025

STING Triggers ZBP1 Necroptosis Without TNFR1

August 21, 2025

Toxoplasma, IL-1 Cause DNA Damage, Cognitive Decline

August 21, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Wearable Devices Improve Parkinson’s Medication Adjustments: Trial

Beijing Tiantan Hospital Researchers Develop Innovative One-Stage Hybrid Surgery for Brain and Spine Tumors

On-Chip All-Dielectric Metasurface Enables Creation of Topological Exceptional Points

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.